FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313543612> ?p ?o ?g. }

• W4313543612 endingPage "e456" @default.
• W4313543612 startingPage "e449" @default.
• W4313543612 abstract "PURPOSE: Several new treatment combinations have been approved in metastatic renal cell carcinoma (mRCC). To determine the optimal therapy on the basis of cost and health outcomes, we performed a cost-effectiveness analysis of approved immunotherapy-tyrosine kinase inhibitor/immunotherapy drug combinations and sunitinib using public payer acquisition costs in the United States. METHODS: We constructed a decision model with a 10-year time horizon. The seven treatment drug strategies included atezolizumab + bevacizumab, avelumab + axitinib, pembrolizumab + axitinib, nivolumab + ipilimumab (NI), nivolumab + cabozantinib, lenvatinib + pembrolizumab, and sunitinib. The effectiveness outcome in our model was quality-adjusted life-years (QALYs) with utility values on the basis of the published literature. Costs included drug acquisition costs and costs for management of grade 3-4 drug-related adverse events. We used a partitioned survival model in which patients with mRCC transitioned between three health states (progression-free, progressive disease, and death) at monthly intervals on the basis of parametric survival function estimated from published survival curves. To determine cost-effectiveness, we constructed incremental cost-effectiveness ratios (ICERs) by dividing the difference in cost by the difference in effectiveness between nondominated treatments. RESULTS: The least expensive treatment was sunitinib ($357,948 US dollars [USD]-$656,100 USD), whereas the most expensive was either lenvatinib + pembrolizumab or pembrolizumab + axitinib ($959,302 USD-$1,403,671 USD). NI yielded the most QALYs (3.6), whereas avelumab + axitinib yielded the least (2.5). NI had an incremental ICER of $297,465 USD-$348,516 USD compared with sunitinib. In sensitivity analyses, this ICER fell below $150,000 USD/QALY if the initial 4-month cost of NI decreased by 22%-38%. CONCLUSION: NI was the most effective combination for mRCC, but at a willingness-to-pay threshold of $150,000 USD/QALY, sunitinib was the most cost-effective approach." @default.
• W4313543612 created "2023-01-06" @default.
• W4313543612 creator A5020638442 @default.
• W4313543612 creator A5021900842 @default.
• W4313543612 creator A5051563047 @default.
• W4313543612 creator A5058217274 @default.
• W4313543612 creator A5087850577 @default.
• W4313543612 date "2023-03-01" @default.
• W4313543612 modified "2023-09-26" @default.
• W4313543612 title "Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective" @default.
• W4313543612 cites W1985943243 @default.
• W4313543612 cites W2005295931 @default.
• W4313543612 cites W2067763315 @default.
• W4313543612 cites W2100722947 @default.
• W4313543612 cites W2751214186 @default.
• W4313543612 cites W2755525655 @default.
• W4313543612 cites W2792937256 @default.
• W4313543612 cites W2794182884 @default.
• W4313543612 cites W2796140875 @default.
• W4313543612 cites W2910482049 @default.
• W4313543612 cites W2911812451 @default.
• W4313543612 cites W2913745075 @default.
• W4313543612 cites W2915456024 @default.
• W4313543612 cites W2943887705 @default.
• W4313543612 cites W2989903818 @default.
• W4313543612 cites W3023072291 @default.
• W4313543612 cites W3044459469 @default.
• W4313543612 cites W3083663711 @default.
• W4313543612 cites W3084527163 @default.
• W4313543612 cites W3092591340 @default.
• W4313543612 cites W3093338574 @default.
• W4313543612 cites W3096611616 @default.
• W4313543612 cites W3131063362 @default.
• W4313543612 cites W3134949580 @default.
• W4313543612 cites W3154274729 @default.
• W4313543612 cites W3169039714 @default.
• W4313543612 cites W4205821319 @default.
• W4313543612 cites W4206841660 @default.
• W4313543612 cites W4207018755 @default.
• W4313543612 cites W4210573911 @default.
• W4313543612 cites W4229036764 @default.
• W4313543612 doi "https://doi.org/10.1200/op.22.00447" @default.
• W4313543612 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36599117" @default.
• W4313543612 hasPublicationYear "2023" @default.
• W4313543612 type Work @default.
• W4313543612 citedByCount "0" @default.
• W4313543612 crossrefType "journal-article" @default.
• W4313543612 hasAuthorship W4313543612A5020638442 @default.
• W4313543612 hasAuthorship W4313543612A5021900842 @default.
• W4313543612 hasAuthorship W4313543612A5051563047 @default.
• W4313543612 hasAuthorship W4313543612A5058217274 @default.
• W4313543612 hasAuthorship W4313543612A5087850577 @default.
• W4313543612 hasBestOaLocation W43135436121 @default.
• W4313543612 hasConcept C112930515 @default.
• W4313543612 hasConcept C121608353 @default.
• W4313543612 hasConcept C126322002 @default.
• W4313543612 hasConcept C143998085 @default.
• W4313543612 hasConcept C2776264508 @default.
• W4313543612 hasConcept C2776539811 @default.
• W4313543612 hasConcept C2776694085 @default.
• W4313543612 hasConcept C2777381376 @default.
• W4313543612 hasConcept C2777472916 @default.
• W4313543612 hasConcept C2777701055 @default.
• W4313543612 hasConcept C2777802072 @default.
• W4313543612 hasConcept C2778439243 @default.
• W4313543612 hasConcept C2779490328 @default.
• W4313543612 hasConcept C2779761222 @default.
• W4313543612 hasConcept C2780030458 @default.
• W4313543612 hasConcept C2780057760 @default.
• W4313543612 hasConcept C2781064419 @default.
• W4313543612 hasConcept C2781068499 @default.
• W4313543612 hasConcept C2781433595 @default.
• W4313543612 hasConcept C3019080777 @default.
• W4313543612 hasConcept C515549039 @default.
• W4313543612 hasConcept C71924100 @default.
• W4313543612 hasConceptScore W4313543612C112930515 @default.
• W4313543612 hasConceptScore W4313543612C121608353 @default.
• W4313543612 hasConceptScore W4313543612C126322002 @default.
• W4313543612 hasConceptScore W4313543612C143998085 @default.
• W4313543612 hasConceptScore W4313543612C2776264508 @default.
• W4313543612 hasConceptScore W4313543612C2776539811 @default.
• W4313543612 hasConceptScore W4313543612C2776694085 @default.
• W4313543612 hasConceptScore W4313543612C2777381376 @default.
• W4313543612 hasConceptScore W4313543612C2777472916 @default.
• W4313543612 hasConceptScore W4313543612C2777701055 @default.
• W4313543612 hasConceptScore W4313543612C2777802072 @default.
• W4313543612 hasConceptScore W4313543612C2778439243 @default.
• W4313543612 hasConceptScore W4313543612C2779490328 @default.
• W4313543612 hasConceptScore W4313543612C2779761222 @default.
• W4313543612 hasConceptScore W4313543612C2780030458 @default.
• W4313543612 hasConceptScore W4313543612C2780057760 @default.
• W4313543612 hasConceptScore W4313543612C2781064419 @default.
• W4313543612 hasConceptScore W4313543612C2781068499 @default.
• W4313543612 hasConceptScore W4313543612C2781433595 @default.
• W4313543612 hasConceptScore W4313543612C3019080777 @default.
• W4313543612 hasConceptScore W4313543612C515549039 @default.
• W4313543612 hasConceptScore W4313543612C71924100 @default.
• W4313543612 hasIssue "3" @default.

• next